Meeting
2023 ASCO Annual Meeting
Using machine learning to characterize lung cancer microenvironment and the development of a model to predict the presence of similar microenvironment in other cancers.
Authors
Ahmad Charifa
Genomic Testing Cooperative, Irvine, CA
Ahmad Charifa , Hong Zhang , Andrew Ip , Jeffrey Estella , Wanlong Ma , Arash Mohtashamian , Martin Gutierrez , Andrew L Pecora , Andre Goy , Maher Albitar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2634)
DOI
10.1200/JCO.2023.41.16_suppl.2634
Abstract #
2634
Poster Bd #
476
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Defining the immune microenvironment in myelodysplastic syndrome and acute myeloid leukemia using machine learning.
First Author: Maher Albitar
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Analysis of HLA gene expression in patients with dMMR/MSI-H colorectal carcinoma resistant to immune checkpoint inhibitors.
First Author: Heinz-Josef Lenz
Poster
2022 ASCO Annual Meeting
Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers.
First Author: Mohamed E. Salem